Aignostics, a Berlin, Germany-based artificial intelligence (AI) company turning multi-modal pathology data into insights, raised $34M in Series B funding.
The round was led by ATHOS, with participation from Mayo Clinic and growth financing from HTGF, alongside support from existing investors Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and VC Fonds Technologie managed by IBB Ventures.
The company intends to use the funds to build new product offerings for biopharmaceutical clients, accelerate growth within the United States (US), and develop foundation models for pathology in collaboration with Mayo Clinic.
Led by CEO Viktor Matyas, Aignostics is an artificial intelligence (AI) company transforming complex multimodal pathology data into insights: It does it by combining proprietary access to multimodal clinical data, technologies, and science, and developing products and services for precision medicine. Through collaborations with its biopharma partners, it supports drug discovery, translational research, clinical trials, and CDx development. Established in 2018, Aignostics is a spin-off from Charité Berlin, with operations in Berlin and New York.
FinSMEs
29/10/2024